Literature DB >> 25430048

Atrial fibrillation (acute onset).

Gregory Y H Lip1, Stavros Apostolakis.   

Abstract

INTRODUCTION: Acute atrial fibrillation is rapid, irregular, and chaotic atrial activity of recent onset. Various definitions of acute atrial fibrillation have been used in the literature, but for the purposes of this review we have included studies where atrial fibrillation may have occurred up to 7 days previously. Risk factors for acute atrial fibrillation include increasing age, cardiovascular disease, alcohol, diabetes, and lung disease. Acute atrial fibrillation increases the risk of stroke and heart failure. The condition resolves spontaneously within 24 to 48 hours in more than 50% of people; however, many people will require interventions to control heart rate or restore sinus rhythm. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent embolism, for conversion to sinus rhythm, and to control heart rate in people with recent-onset atrial fibrillation (within 7 days) who are haemodynamically stable? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 26 studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review, we present information relating to the effectiveness and safety of the following interventions: amiodarone, antithrombotic treatment before cardioversion, atenolol, bisoprolol, carvedilol, digoxin, diltiazem, direct current cardioversion, flecainide, metoprolol, nebivolol, propafenone, sotalol, timolol, and verapamil.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25430048      PMCID: PMC4246362     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  66 in total

Review 1.  Management of atrial fibrillation.

Authors:  Gregory Y H Lip; Antonio Tello-Montoliu
Journal:  Heart       Date:  2006-08       Impact factor: 5.994

2.  Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the Cardiac Arrhythmia Suppression Trial. CAST Investigators.

Authors:  T Akiyama; Y Pawitan; H Greenberg; C S Kuo; R A Reynolds-Haertle
Journal:  Am J Cardiol       Date:  1991-12-15       Impact factor: 2.778

3.  Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicentre study.

Authors:  A Capucci; G Q Villani; D Aschieri; M Piepoli
Journal:  Int J Cardiol       Date:  1999-02-28       Impact factor: 4.164

4.  Risk factors for systemic embolism in patients with paroxysmal atrial fibrillation.

Authors:  R Corbalán; D Arriagada; S Braun; J Tapia; I Huete; A Kramer; A Chávez
Journal:  Am Heart J       Date:  1992-07       Impact factor: 4.749

5.  The beneficial effects of verapamil in chronic atrial fibrillation.

Authors:  H O Klein; H Pauzner; E Di Segni; D David; E Kaplinsky
Journal:  Arch Intern Med       Date:  1979-07

6.  Conversion of recent-onset atrial fibrillation to sinus rhythm: effects of different drug protocols.

Authors:  G Boriani; M Biffi; A Capucci; G Botto; T Broffoni; M Ongari; G Trisolino; I Rubino; M Sanguinetti; A Branzi; B Magnani
Journal:  Pacing Clin Electrophysiol       Date:  1998-11       Impact factor: 1.976

7.  Verapamil for control of ventricular rate in paroxysmal supraventricular tachycardia and atrial fibrillation or flutter: a double-blind randomized cross-over study.

Authors:  H L Waxman; R J Myerburg; R Appel; R J Sung
Journal:  Ann Intern Med       Date:  1981-01       Impact factor: 25.391

Review 8.  Rate issues in atrial fibrillation: consequences of tachycardia and therapy for rate control.

Authors:  B Schumacher; B Lüderitz
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

9.  Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates.

Authors:  W B Kannel; P A Wolf; E J Benjamin; D Levy
Journal:  Am J Cardiol       Date:  1998-10-16       Impact factor: 2.778

10.  Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter. The Diltiazem-Atrial Fibrillation/Flutter Study Group.

Authors:  D M Salerno; V C Dias; R E Kleiger; V H Tschida; R J Sung; M Sami; L V Giorgi
Journal:  Am J Cardiol       Date:  1989-05-01       Impact factor: 2.778

View more
  1 in total

1.  Intravenous Magnesium Sulfate Reduces the Need for Antiarrhythmics during Acute-Onset Atrial Fibrillation in Emergency and Critical Care.

Authors:  Emanuele Gilardi; Fulvio Pomero; Enrico Ravera; Andrea Piccioni; Michele Cosimo Santoro; Nicola Bonadia; Annamaria Carnicelli; Luca Di Maurizio; Luca Sabia; Yaroslava Longhitano; Angela Saviano; Veronica Ojetti; Gabriele Savioli; Christian Zanza; Francesco Franceschi
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.